7 completed, 1 suspended, 1 terminated, 1 withdrawn. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Suspended 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Suspended 1, Terminated 1 |
Follow gusacitinib: new trials by email Literature Review of gusacitinib trials Research Report on gusacitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus Gusacitinib - Systemic Lupus Erythematosus | Phase 1 | Withdrawn | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2025-01-22 | 2025-03-13 | |
| Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor ASN-002 - Basal Cell Carcinoma, Basal Cell Nevus Syndrome | Phase 2 | Completed | Ascend Biopharmaceuticals Ltd | 21 | 2020-07-16 | 2024-04-10 |
| Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema ASN002, Placebo Oral Tablet - Chronic Hand Dermatitis | Phase 2 | Completed | Asana BioSciences | 97 | 2019-01-03 | 2023-05-09 |
| Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects [14C] ASN002 - Healthy Volunteer | Phase 1 | Completed | Asana BioSciences | 8 | 2018-10-11 | 2020-05-28 |
| Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis ASN002 - Atopic Dermatitis | Phase 2 | Terminated | Asana BioSciences | 162 | 2018-09-29 | 2023-09-18 |
| Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT) ASN002, Placebo Oral Tablet - Atopic Dermatitis | Phase 2 | Completed | Asana BioSciences | 244 | 2018-07-05 | 2023-07-03 |
| Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS) ASN-002 - Basal Cell Carcinoma in Basal Cell Nevus Syndrome | Phase 1 / Phase 2 | Suspended | Ascend Biopharmaceuticals Ltd | 24 | 2017-12-01 | 2023-02-06 |
| A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis ASN002, Placebo Oral Tablet - Dermatitis, Atopic, Dermatitis Eczema | Phase 1 | Completed | Asana BioSciences | 36 | 2017-04-12 | 2023-05-10 |
| Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers ASN002 - Healthy Volunteers | Phase 1 | Completed | Asana BioSciences | 22 | 2016-07-01 | 2023-04-14 |
| A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma ASN-002, 5-FU - Basal Cell Nevus Syndrome, Skin Neoplasm | Phase 1 / Phase 2 | Completed | Ascend Biopharmaceuticals Ltd | 16 | 2015-09-01 | 2018-06-06 |
Eczema (4) · Basal Cell Nevus Syndrome (3) · Dermatitis, Atopic (3) · Carcinoma, Basal Cell (2) · Lupus Erythematosus, Systemic (1) · Lymphoma, Follicular (1) · Skin Neoplasms (1)
Asana BioSciences (6) · Ascend Biopharmaceuticals Ltd (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
United States (8) · Canada (4) · Australia (2) · Germany (1)
David Zammit, Ph.D. (4) · Gregory Siller (2) · Anna Bar (1) · Clement Leong (1) · Clement Leong, Ph.D (1) · David Wyatt, MD (1) · Lynda Spelman (1) · Niranjan Rao, PhD (1) · Rodney Sinclair (1) · Sarfaraz A Hasni, M.D. (1)